|
|Section2= |Section3= }} Motesanib (AMG 706) is an experimental drug candidate originally developed by Amgen but is now being investigated by the Takeda Pharmaceutical Company. It is an orally administered small molecule belonging to angiokinase inhibitor class which acts as an antagonist of VEGF receptors, platelet-derived growth factor receptors, and stem cell factor receptors. It is used as the phosphate salt motesanib diphosphate. ==Clinical trials== Motesanib was originally investigated for effectiveness against advanced nonsquamous non-small-cell lung cancer (NSCLC), with Phase II trials indicating an effectiveness comparable to bevacizumab when they were both used in combination with paclitaxel/carboplatin. However a later and more detailed Phase III trial failed to show any benefit for the treatment of NSCLC.〔 A second Phase III trial was started in 2012,〔(【引用サイトリンク】url=http://www.takeda.com/news/2012/20120726_3985.html )〕 which focused on patients from Asian backgrounds (performed on the bases of subgroup analysis) however this also failed to meet its primary endpoint.〔(【引用サイトリンク】url=http://www.takeda.com/news/2015/20150217_6909.html )〕 The drug has undergone a Phase II evaluation as first-line therapy for breast cancer〔 however this study found no evidence to support further investigation. Phase II testing against persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas was also unsuccessful. There have also been 2 separate Phase II clinical trials for thyroid cancer which have both shown promising results.〔(Motesanib Diphosphate Provides Anticancer Activity Among Patients with Progressive Thyroid Cancer ), CancerConnect.com〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Motesanib」の詳細全文を読む スポンサード リンク
|